Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 5;11(11):525-532.
doi: 10.1093/jpids/piac087.

How I Approach Leishmaniasis: Diagnosis and Treatment in the United States

Affiliations

How I Approach Leishmaniasis: Diagnosis and Treatment in the United States

Tara E Ness et al. J Pediatric Infect Dis Soc. .

Abstract

Leishmaniasis is a vector-borne disease caused by over 20 species of obligate intracellular protozoa belonging to the genus Leishmania. Leishmaniasis has a global distribution, including in the United States, and can cause a spectrum of clinical syndromes, including cutaneous, mucosal, and visceral diseases depending on host factors and the infecting Leishmania spp. Accurate diagnosis, including Leishmania species identification, is an important step to guide the most appropriate therapeutic intervention. Antileishmanial therapy is dependent on the Leishmania spp. identified, the clinical syndrome, and the child's immune system. However, many treatment regimens for children have been extrapolated from adult clinical trials, which may lead to underdosing and subsequent poor outcomes in infected children. Additional research is urgently needed to help guide therapy for children and determine appropriate antileishmanial agents, doses, and treatment courses for children with leishmaniasis.

Keywords: leishmaniasis; neglected tropical disease; parasites; tropical medicine.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Summary of leishmaniasis.
Figure 2.
Figure 2.
Cutaneous leishmaniasis lesion caused by L.V. braziliensis (photo credit: Jill Weatherhead).

References

    1. World Health Organization. Global leishmaniasis surveillance: 2019–2020, a baseline for the 2030 roadmap. Wkly Epidemiol Rec 2021;96:401–19.
    1. Mursalin SM, Sheikh Ali SA, Crilly J, Bino S. . Leishmaniasis Gap Analysis Report and Action Plan: Strengthening the Epidemiologial Surveillance, Diagnosis and Treatment of Visceral and Cutaneous Leishmaniasis in Albania, Jordan and Pakistan. Connecting Organisations for Regional Disease Surveillance (CORDS); 2015. http://www.mecidsnetwork.org/sites/default/files/FINAL%20Leishmaniasis%2....
    1. Nweze JA, Nweze EI, Onoja US.. Nutrition, malnutrition, and leishmaniasis. Nutrition 2020; 73:110712. - PubMed
    1. Cota GF, de Sousa MR, Rabello A.. Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review. PLoS NeglTrop Dis 2011; 5:e1153. - PMC - PubMed
    1. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001; 95:239–43. - PubMed

Substances